23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Halozyme Therapeutics, Inc. › 2025-2026

Halozyme Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Halozyme Therapeutics, Inc.’s Form 8-K, filed May 7, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 601Asset managers, any item
  • 2,974Fund votes
  • May 5, 2026Meeting date

Results at a glance

Meeting of May 5, 2026: 4 items on Halozyme Therapeutics, Inc.’s Form 8-K, filed May 7, 2026: 2 approved · 2 passed (calculated).

Dissent

Notable dissent: 1 director (11.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Halozyme Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Halozyme Therapeutics, Inc.

These tallies are Halozyme Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 7, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Halozyme Therapeutics, Inc. — official shareholder meeting results, meeting held May 5, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Bernadette Connaughton 89,053,7345,068,160127,131 --9,889,219 95%Passed (calculated)—
Elect Director: Matthew L. Posard 82,739,43310,236,8781,272,714 --9,889,219 89%Passed (calculated)—
2. Advisory vote on the compensation of the Company's named executive officers 84,682,5189,311,426255,081 --9,889,219 90%Approved—
3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 103,197,579849,43391,232 ---- 99.2%Approved—

Source: Halozyme Therapeutics, Inc., Form 8-K, filed with the SEC on May 7, 2026 — read the filing on EDGAR.

How asset managers voted at the Halozyme Therapeutics, Inc. 2025-2026 meeting

601 asset managers disclosed a vote on at least one Halozyme Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Bernadette Connaughton

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 89,053,734AGAINST: 5,068,160
Details: description as filed, official tally, votes by 145 asset managers

Description as filed by funds: Election of Class I Directors: Bernadette Connaughton

Halozyme Therapeutics, Inc.’s own tally for this item (“Elect Director: Bernadette Connaughton”): 89,053,734 for, 5,068,160 against, per its Form 8-K filed May 7, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 145 asset managers below reported 45,116,992 for, 1,629,505 against, 31,020 abstained, 90 not voted.

FOR
FOR: 45,116,992AGAINST: 1,629,505ABSTAIN: 31,020NOT VOTED: 90
Largest asset managers voting on “Election of Class I Directors: Bernadette Connaughton” at Halozyme Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard11,406,61311 00For
BlackRock7,468,2460 00For
Fidelity2,427,3640 00For
Invesco2,371,3790 00For
State Street2,337,9070 00For
First Trust1,487,6560 00For
John Hancock137,1581,168,773 00Mixed
Charles Schwab1,257,7060 00For
Federated Hermes1,113,8510 00For
Capitol Series Trust898,2550 00For
Delaware/Macquarie875,2410 00For
Pacer Funds Trust849,7340 00For
Capital Group830,3850 00For
Putnam561,1940 00For
TIAA551,1840 00For
Dimensional521,3180 00For
WILLIAM BLAIR FUNDS433,9650 00For
Bridge Builder Trust313,876101,043 00Mixed
Jackson National407,5490 00For
Nationwide380,9860 00For
EA Series Trust379,2840 00For
Calamos349,9300 00For
PROFESSIONALLY MANAGED PORTFOLIOS347,0500 00For
Victory Capital325,2890 00For
JANUS INVESTMENT FUND321,0700 00For

Showing the 25 largest of 145 asset managers. All 145 are in the interactive database (link above).

Elect Director: Matthew L. Posard

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 82,739,433AGAINST: 10,236,878
Details: description as filed, official tally, votes by 145 asset managers

Description as filed by funds: Election of Class I Directors: Matthew L. Posard

Halozyme Therapeutics, Inc.’s own tally for this item (“Elect Director: Matthew L. Posard”): 82,739,433 for, 10,236,878 against, per its Form 8-K filed May 7, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 145 asset managers below reported 42,565,188 for, 4,181,306 against, 31,023 abstained, 90 not voted.

FOR
FOR: 42,565,188AGAINST: 4,181,306ABSTAIN: 31,023NOT VOTED: 90
Largest asset managers voting on “Election of Class I Directors: Matthew L. Posard” at Halozyme Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard11,400,1396,482 30For
BlackRock7,468,2460 00For
Fidelity2,427,3640 00For
Invesco2,371,3790 00For
State Street20,5642,317,343 00Against
First Trust1,487,6560 00For
John Hancock137,1581,168,773 00Mixed
Charles Schwab1,257,7060 00For
Federated Hermes1,113,8510 00For
Capitol Series Trust898,2550 00For
Delaware/Macquarie875,2410 00For
Pacer Funds Trust849,7340 00For
Capital Group830,3850 00For
Putnam561,1940 00For
TIAA551,1840 00For
Dimensional521,3180 00For
WILLIAM BLAIR FUNDS433,9650 00For
Bridge Builder Trust313,876101,043 00Mixed
Jackson National407,5490 00For
Nationwide380,9860 00For
EA Series Trust379,2840 00For
Calamos349,9300 00For
PROFESSIONALLY MANAGED PORTFOLIOS347,0500 00For
Victory Capital325,2890 00For
JANUS INVESTMENT FUND321,0700 00For

Showing the 25 largest of 145 asset managers. All 145 are in the interactive database (link above).

Advisory vote on the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 15 wordings of this item as funds reported it.

90% Approved · of votes cast

FOR 90%
FOR: 84,682,518AGAINST: 9,311,426

Prior year: 96.1% for (May 1, 2025 meeting) ▼ 6.0 pts

Details: description as filed, official tally, votes by 601 asset managers

Description as filed by funds: To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.

Halozyme Therapeutics, Inc.’s own tally for this item (“2. The advisory vote on the compensation of the Company's named executive officers”): 84,682,518 for, 9,311,426 against — passed, per its Form 8-K filed May 7, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 145 asset managers voting on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.” at Halozyme Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard11,406,61310 00For
BlackRock7,468,2460 00For
Fidelity2,427,3640 00For
Invesco2,371,3790 00For
State Street20,6732,317,234 00Against
First Trust1,487,6560 00For
John Hancock1,305,9310 00For
Charles Schwab1,257,7060 00For
Federated Hermes1,113,8510 00For
Capitol Series Trust898,2550 00For
Delaware/Macquarie875,2410 00For
Pacer Funds Trust849,7340 00For
Capital Group830,3850 00For
Putnam561,1940 00For
TIAA551,1840 00For
Dimensional521,3180 00For
WILLIAM BLAIR FUNDS433,9650 00For
Bridge Builder Trust414,9190 00For
Jackson National407,5490 00For
Nationwide380,9860 00For
EA Series Trust379,2840 00For
Calamos349,9300 00For
PROFESSIONALLY MANAGED PORTFOLIOS347,0500 00For
Victory Capital325,2890 00For
JANUS INVESTMENT FUND321,0700 00For

Fund voting reports, all 145 managers: 44,065,605 for, 2,614,702 against, 31,020 abstained, 120 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 486 asset managers voting on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.” at Halozyme Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
State Street61,4814,760,960 00Against
BlackRock3,386,9881,579 00For
Invesco3,056,4520 00For
GEODE CAPITAL MANAGEMENT, LLC2,468,7930 00For
SNYDER CAPITAL MANAGEMENT L P2,153,8750 00For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC2,098,2210 00For
Boston Partners2,028,8810 00For
Janus Henderson1,845,7940 00For
AllianceBernstein1,691,6040 00For
JUPITER ASSET MANAGEMENT LTD1,567,2420 00For
Federated Hermes1,534,1630 00For
FULLER & THALER ASSET MANAGEMENT, INC.1,344,6860 00For
Charles Schwab1,276,6160 00For
GW&K Investment Management, LLC228,3580 00For
CONGRESS ASSET MANAGEMENT CO1,200,5630 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST1,125,6050 00For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP1,095,7400 00For
Stephens Investment Management Group LLC1,005,8720 00For
Vanguard949,6980 00For
Northern Trust924,6220 00For
Putnam846,8080 00For
Capital Group830,3850 00For
LOS ANGELES CAPITAL MANAGEMENT LLC753,7160 00For
UBS0644,161 00Against
Handelsbanken Fonder AB591,8690 00For

Institutional-manager reports, all 486 managers: 51,280,504 for, 6,885,808 against, 94,279 abstained, 23,173 not voted, 1,030,053 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.2% Approved · of votes cast

FOR 99.2%
FOR: 103,197,579AGAINST: 849,433

Prior year: 99.4% for (May 1, 2025 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 145 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Halozyme Therapeutics, Inc.’s own tally for this item (“3. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 103,197,579 for, 849,433 against — passed, per its Form 8-K filed May 7, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Halozyme Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 145 asset managers below reported 46,739,895 for, 6,602 against, 31,020 abstained, 90 not voted.

FOR
FOR: 46,739,895AGAINST: 6,602ABSTAIN: 31,020NOT VOTED: 90
Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FO” at Halozyme Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard11,400,1536,471 00For
BlackRock7,468,2460 00For
Fidelity2,427,3640 00For
Invesco2,371,3790 00For
State Street2,337,798109 00For
First Trust1,487,6560 00For
John Hancock1,305,9310 00For
Charles Schwab1,257,7060 00For
Federated Hermes1,113,8510 00For
Capitol Series Trust898,2550 00For
Delaware/Macquarie875,2410 00For
Pacer Funds Trust849,7340 00For
Capital Group830,3850 00For
Putnam561,1940 00For
TIAA551,1840 00For
Dimensional521,3180 00For
WILLIAM BLAIR FUNDS433,9650 00For
Bridge Builder Trust414,9190 00For
Jackson National407,5490 00For
Nationwide380,9860 00For
EA Series Trust379,2840 00For
Calamos349,9300 00For
PROFESSIONALLY MANAGED PORTFOLIOS347,0500 00For
Victory Capital325,2890 00For
JANUS INVESTMENT FUND321,0700 00For

Showing the 25 largest of 145 asset managers. All 145 are in the interactive database (link above).

Largest Halozyme Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 118,523,000 shares outstanding at the time of that meeting.

Fund voting reports: top Halozyme Therapeutics, Inc. shareholders by shares voted on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 9.62%
2BlackRock 6.30%
3Fidelity 2.05%
4Invesco 2.00%
5State Street 1.97%
6First Trust 1.26%
7John Hancock 1.10%
8Charles Schwab 1.06%
9Federated Hermes 0.94%
10Capitol Series Trust 0.76%
Institutional-manager reports: top Halozyme Therapeutics, Inc. shareholders by shares voted on “To approve, by a non-binding advisory vote, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1State Street 4.07%
2BlackRock 2.86%
3Invesco 2.58%
4GEODE CAPITAL MANAGEMENT, LLC 2.08%
5SNYDER CAPITAL MANAGEMENT L P 1.82%
6WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.77%
7Boston Partners 1.71%
8Janus Henderson 1.56%
9AllianceBernstein 1.43%
10JUPITER ASSET MANAGEMENT LTD 1.32%

Reported Halozyme Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Halozyme Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock13,265,053 11.19%Form 13F, quarter ended March 31, 2026
Vanguard Group11,566,896 9.76%Form 13F, quarter ended March 31, 2026
State Street Corporation6,053,007 5.11%Proxy statement (DEF 14A), table as of March 9, 2026
Invesco4,012,494 3.39%Form 13F, quarter ended March 31, 2026
Morgan Stanley2,658,299 2.24%Form 13F, quarter ended March 31, 2026
Helen I. Torley2,208,873 1.86%Proxy statement (DEF 14A), table as of March 9, 2026
Dimensional Fund Advisors2,079,827 1.75%Form 13F, quarter ended March 31, 2026
D.E. Shaw1,899,408 1.60%Form 13F, quarter ended March 31, 2026
Two Sigma1,584,961 1.34%Form 13F, quarter ended March 31, 2026
Charles Schwab1,289,533 1.09%Form 13F, quarter ended March 31, 2026

Percentages above are of 118,523,000 shares outstanding, as reported by Halozyme Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Halozyme Therapeutics, Inc.'s shareholder meeting held May 5, 2026, in the 2025-2026 proxy season, 601 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 2,974 separate fund positions. On the most widely held item on that ballot — To approve, by a non-binding advisory vote, the compensation of the Company's named executive… — Halozyme Therapeutics, Inc.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Halozyme Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 7, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Halozyme Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Halozyme Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Halozyme Therapeutics (HALO) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/halozyme-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.